(Q36648756)

15 August 2017

Is it possible to accurately determine content of botulinum neurotoxin type A in drug products? (English)

1 reference

15 August 2017

Dorothea Sesardic

1

1 reference

15 August 2017

1 January 2010

1 reference

15 August 2017

1 reference

15 August 2017

10

1 reference

15 August 2017

2

1 reference

15 August 2017

91-92

1 reference

Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®.

15 August 2017

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3585689

Therapeutic botulinum type A toxin: factors affecting potency.

30 September 2017

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3585689

Dose standardisation of botulinum toxin.

28 June 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3585689

Role for standards in assays of botulinum toxins: international collaborative study of three preparations of botulinum type A toxin

28 June 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20698717

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Immunological detection of Clostridium botulinum toxin type A in therapeutic preparations

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20698717

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.2165/11584910-000000000-00000

1 reference

15 August 2017

1 reference

PMC publication ID

3585689

15 August 2017

PubMed publication ID

20698717

1 reference

PMC publication ID

3585689